[ 68 Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ 18 F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study
Journal of Nuclear Medicine · 2026
DOI: 10.2967/jnumed.125.270850 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Timo Bartel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany; timo.bartel@uk-essen.de. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Gastrointestinal Stromal Tumors, Contrast Media. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Although contrast-enhanced CT (ceCT) and 2-[18F]FDG PET/CT remain standard imaging modalities, both exhibit limitations in detecting small peritoneal metastases and tumors with low metabolic activity. 68Ga-labeled fibroblast activation protein inhibitors (FAPIs) have shown promising results in various malignancies; however, comparative data on GISTs are limited. This study aimed to assess the diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT in comparison with 2-[18F]FDG PET/CT and ceCT, including evaluation of interreader reproducibility and clinical impact.
Methods
This study retrospectively reviewed 25 patients with histopathologically confirmed GISTs undergoing [68Ga]Ga-FAPI-46 PET/CT as part of a prospective observational study (NCT04571086). All patients (n = 25) underwent additional clinical 2-[18F]FDG PET/CT; ceCT was performed for 23 of 25 patients. Imaging was assessed per patient and per region (primary tumor, lymph nodes, and visceral and bone metastases), and a composite reference standard that included histopathology, follow-up imaging, and clinical data was applied. Interreader agreement, stratified by experience level, was analyzed using Cohen κ (κCohen). Referring physicians completed questionnaires before and after imaging to determine clinical impact.
Results
In total, 28 validated regions (n = 20 patients) were included in the diagnostic efficacy analysis. Per region, ceCT and [68Ga]Ga-FAPI-46 PET/CT demonstrated comparable sensitivity (83% vs. 81%), followed by 2-[18F]FDG PET/CT (65%). [68Ga]Ga-FAPI-46 PET/CT demonstrated the highest region-based positive predictive value (100%). The liver tumor-to-background ratio was significantly higher for [68Ga]Ga-FAPI-46 PET/CT than for 2-[18F]FDG PET/CT (median, 7.6 vs. 5.9; P = 0.034), whereas overall tumor uptake showed no significant difference. Changes in clinical management attributable to [68Ga]Ga-FAPI-46 PET/CT were observed for 6 of 24 patients (25%), including 1 major change. Interreader agreement for [68Ga]Ga-FAPI-46 PET/CT varied with reader experience, showing the highest concordance between high- and intermediate-experience readers (κCohen = 0.87 per patient and 0.47-1.00 across regions), whereas comparisons involving less experienced readers yielded lower agreement (κCohen = 0.00-0.60). Conclusion: [68Ga]Ga-FAPI-46 PET/CT demonstrated diagnostic sensitivity comparable to ceCT and superior to 2-[18F]FDG PET/CT for patients with GISTs. High diagnostic performance, especially in hepatic and peritoneal metastases, and relevant clinical impact support a role for [68Ga]Ga-FAPI-46 PET/CT as complementary imaging modality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany; timo.bartel@uk-essen.de.
- German Cancer Consortium, Partner Site Essen, Essen, Germany.
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Diagnostic and Interventional Radiology, West German Cancer Center, University Hospital Essen, Essen, Germany; and.
- Bridge Institute of Experimental Tumor Therapy and Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Zitieren
APA
Bartel, T., Pabst, K. M., Barg, C., Berliner, C. A., Hamacher, R., Bauer, S., Falkenhorst, J., Kessler, L., Nader, M., Barbato, F., Siveke, J. T., Herrmann, K., & Fendler, W. P. (2026). [ 68 Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ 18 F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270850
Vancouver
Bartel T, Pabst KM, Barg C, Berliner CA, Hamacher R, Bauer S, et al. [ 68 Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ 18 F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270850
BibTeX
@article{Bartel2026,
author = {Bartel, Timo and Pabst, Kim M and Barg, Christina and Berliner, Christoph A and Hamacher, Rainer and Bauer, Sebastian and Falkenhorst, Johanna and Kessler, Lukas and Nader, Michael and Barbato, Francesco and Siveke, Jens T and Herrmann, Ken and Fendler, Wolfgang P},
title = {[ 68 Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ 18 F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.270850}
}
EUVIMED